Romain Guièze

2.8k total citations
61 papers, 868 citations indexed

About

Romain Guièze is a scholar working on Genetics, Hematology and Pathology and Forensic Medicine. According to data from OpenAlex, Romain Guièze has authored 61 papers receiving a total of 868 indexed citations (citations by other indexed papers that have themselves been cited), including 40 papers in Genetics, 24 papers in Hematology and 23 papers in Pathology and Forensic Medicine. Recurrent topics in Romain Guièze's work include Chronic Lymphocytic Leukemia Research (37 papers), Lymphoma Diagnosis and Treatment (22 papers) and Acute Myeloid Leukemia Research (16 papers). Romain Guièze is often cited by papers focused on Chronic Lymphocytic Leukemia Research (37 papers), Lymphoma Diagnosis and Treatment (22 papers) and Acute Myeloid Leukemia Research (16 papers). Romain Guièze collaborates with scholars based in France, United States and Germany. Romain Guièze's co-authors include Catherine J. Wu, Olivier Tournilhac, Grégory Lazarian, Jacques‐Olivier Bay, Richard Lemal, Christophe Willekens, Hervé Dombret, Pierre Feugier, Anne‐Sophie Michallet and Alain Delmer and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Romain Guièze

58 papers receiving 854 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Romain Guièze France	15	386	318	254	210	195	61	868
Dong Soon Lee South Korea	18	252 0.7×	575 1.8×	91 0.4×	329 1.6×	132 0.7×	75	882
Gianluigi Castoldi Italy	19	278 0.7×	483 1.5×	180 0.7×	237 1.1×	330 1.7×	36	957
Seongseok Yun United States	18	248 0.6×	344 1.1×	206 0.8×	306 1.5×	147 0.8×	79	1.1k
Mojtaba Akhtari United States	19	190 0.5×	444 1.4×	105 0.4×	290 1.4×	263 1.3×	77	1.2k
Deborah Fuchs United States	8	310 0.8×	606 1.9×	102 0.4×	368 1.8×	89 0.5×	20	882
June Li United States	17	119 0.3×	654 2.1×	107 0.4×	220 1.0×	199 1.0×	37	1.0k
Angeline Van Orshoven Belgium	15	291 0.8×	488 1.5×	163 0.6×	183 0.9×	111 0.6×	29	735
Zeba N. Singh United States	15	130 0.3×	497 1.6×	127 0.5×	360 1.7×	182 0.9×	54	984
Filiz Şen United States	16	163 0.4×	117 0.4×	278 1.1×	112 0.5×	124 0.6×	42	623
Alison R. Sehgal United States	13	143 0.4×	326 1.0×	174 0.7×	373 1.8×	227 1.2×	52	1.1k

Countries citing papers authored by Romain Guièze

Since Specialization

Citations

This map shows the geographic impact of Romain Guièze's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Romain Guièze with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Romain Guièze more than expected).

Fields of papers citing papers by Romain Guièze

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Romain Guièze. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Romain Guièze. The network helps show where Romain Guièze may publish in the future.

Co-authorship network of co-authors of Romain Guièze

This figure shows the co-authorship network connecting the top 25 collaborators of Romain Guièze. A scholar is included among the top collaborators of Romain Guièze based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Romain Guièze. Romain Guièze is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Chong, Stephen Jun Fei, Kartini Iskandar, Chuqi Wang, et al.. (2025). Superoxide-mediated phosphorylation and stabilization of Mcl-1 by AKT underlie venetoclax resistance in hematologic malignancies. Leukemia. 39(10). 2477–2491. 2 indexed citations

Nguyen‐Khac, Florence, Marine Baron, Romain Guièze, et al.. (2024). Prognostic impact of genetic abnormalities in 536 first‐line chronic lymphocytic leukaemia patients without 17p deletion treated with chemoimmunotherapy in two prospective trials: Focus on IGHV‐mutated subgroups (a FILO study). British Journal of Haematology. 205(2). 495–502. 2 indexed citations

Ysebaert, Loïc, Emmanuelle Ferrant, Anne‐Sophie Michallet, et al.. (2023). Outcomes of CLL Patients Exposed to Venetoclax+/-R after Ibrutinib in France: The Resist Retrospective Study from the Filo-CLL Group. Blood. 142(Supplement 1). 3273–3273. 1 indexed citations

Guièze, Romain, et al.. (2021). Syndrome de Richter : prise en charge diagnostique et thérapeutique. Bulletin du Cancer. 108(5). 521–527. 1 indexed citations

Guièze, Romain, et al.. (2021). Anticorps bispecifiques en oncohématologie : applications et perspectives. Bulletin du Cancer. 108(10). S195–S204. 4 indexed citations

Bottardi, Stefania, Romain Guièze, Vincent Bourgoin, et al.. (2020). MNDA controls the expression of MCL-1 and BCL-2 in chronic lymphocytic leukemia cells. Experimental Hematology. 88. 68–82.e5. 13 indexed citations

Lavergne, Rose‐Anne, Thomas Morel, Romain Guièze, et al.. (2020). Hormographiella aspergillata: an emerging basidiomycete in the clinical setting? A case report and literature review. BMC Infectious Diseases. 20(1). 945–945. 7 indexed citations

Quinquenel, Anne, Luc‐Matthieu Fornecker, Rémi Letestu, et al.. (2019). Prevalence of BTK and PLCG2 mutations in a real-life CLL cohort still on ibrutinib after 3 years: a FILO group study. Blood. 134(7). 641–644. 88 indexed citations

Quinquenel, Anne, Luc Matthieu Fornecker, Rémi Letestu, et al.. (2018). High Prevalence of BTK Mutations on Ibrutinib Therapy after 3 Years of Treatment in a Real-Life Cohort of CLL Patients: A Study from the French Innovative Leukemia Organization (FILO) Group. Blood. 132(Supplement 1). 584–584. 8 indexed citations

10.

Detappe, Alexandre, Sijumon Kunjachan, Lucie Sancey, et al.. (2016). Advanced multimodal nanoparticles delay tumor progression with clinical radiation therapy. Journal of Controlled Release. 238. 103–113. 71 indexed citations

11.

Bay, Jacques‐Olivier, et al.. (2016). Rationnel et modalités de prescription de l’ibrutinib dans les hémopathies lymphoïdes B. Bulletin du Cancer. 103(2). 127–137. 1 indexed citations

12.

Adès, Lionel, Thomas Prébet, Aspasia Stamatoullas, et al.. (2016). Lenalidomide combined with intensive chemotherapy in acute myeloid leukemia and higher-risk myelodysplastic syndrome with 5q deletion. Results of a phase II study by the Groupe Francophone Des Myélodysplasies. Haematologica. 102(4). 728–735. 21 indexed citations

13.

Gac, Anne‐Claire, Nabih Azar, Étienne Daguindau, et al.. (2016). Does bendamustine impact the mobilization of peripheral blood stem cells? A multicenter retrospective study of 23 cases. Leukemia & lymphoma. 57(5). 1149–1153. 3 indexed citations

14.

Rossignol, Julien, Louis Terriou, Christophe Willekens, et al.. (2015). Radioimmunotherapy (90Y-Ibritumomab Tiuxetan) for Posttransplant Lymphoproliferative Disorders After Prior Exposure to Rituximab. American Journal of Transplantation. 15(7). 1976–1981. 10 indexed citations

15.

Guièze, Romain & Catherine J. Wu. (2015). Genomic and epigenomic heterogeneity in chronic lymphocytic leukemia. Blood. 126(4). 445–453. 99 indexed citations

16.

Thomas, Xavier, Romain Guièze, Patrice Chevallier, et al.. (2015). GRASPA-AML 2012-01 study (NCT01810705): A multicenter, open, randomized phase 2b trial evaluating ERY001 (L-asparaginase encapsulated in red blood cells) plus low-dose cytarabine vs low-dose cytarabine alone, in treatment of newly diagnosed acute myeloid leukemia (AML) elderly patients, unfit for intensive chemotherapy.. Journal of Clinical Oncology. 33(15_suppl). TPS7099–TPS7099. 4 indexed citations

17.

Leprêtre, Stéphane, Caroline Dartigeas, Hervé Maisonneuve, et al.. (2014). Results of a Phase II Randomizing Intensified Rituximab Pre-Phase Followed By Standard FCR Vs Standard FCR in Previously Untreated Patients with Active B-Chronic Lymphocytic Leukemia (B-CLL). CLL2010FMP (for fit medically patients): A Study of the french Cooperative Group on CLL and WM (FCGCLL/MW) and the “Groupe Ouest-Est d’Etudes Des Leucémies Aigües Et Autres Maladies Du sang” (GOELAMS). Blood. 124(21). 3329–3329. 2 indexed citations

18.

Adès, Lionel, Thomas Prébet, Aspasia Stamatoullas, et al.. (2013). Lenalidomide (LEN) Combined To Intensive Chemotherapy (IC) In AML and Higher Risk MDS With Del 5q. Results Of a Phase I/II Study Of The Groupe Francophone Des Myelodysplasies (GFM). Blood. 122(21). 620–620. 3 indexed citations

19.

Georgin‐Lavialle, Sophie, Claire Aguilar, Romain Guièze, et al.. (2012). Mast Cell Sarcoma: A Rare and Aggressive Entity—Report of Two Cases and Review of the Literature. Journal of Clinical Oncology. 31(6). e90–e97. 33 indexed citations

20.

Guièze, Romain, et al.. (2005). Leucémie à plasmocytes. Hématologie. 11(3). 217–225. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact